How ANGPTL3 affects fat and sugar metabolism in humans
Project 2: Regulation of lipid and glucose metabolism by ANGPTL3 in humans
This study is looking at how a protein called ANGPTL3 affects how our bodies manage fats and sugars, especially in people with certain genetic changes that make them low in this protein, to find new ways to help improve insulin sensitivity and lower the risk of heart disease.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10874523 on NIH RePORTER |
What this research studies
This research investigates the role of ANGPTL3, a protein that influences lipid and glucose metabolism, in humans. By studying individuals with genetic mutations that lead to ANGPTL3 deficiency, researchers aim to understand how this deficiency impacts the body's handling of fats and sugars. The study involves advanced techniques such as in vivo tracer kinetic studies and the use of induced pluripotent stem cells (iPSCs) to explore the cellular mechanisms involved. The goal is to uncover potential therapeutic strategies that could improve insulin sensitivity and reduce cardiovascular disease risk.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with genetic mutations affecting ANGPTL3, as well as those at risk for diabetes and cardiovascular diseases.
Not a fit: Patients without any metabolic disorders or those not affected by lipid metabolism issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve metabolic health and reduce the risk of diabetes and cardiovascular diseases.
How similar studies have performed: Previous research has shown promising results in targeting ANGPTL3 for metabolic improvements, indicating that this approach may be effective.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Stitziel, Nathan Oliver — University of Washington
- Study coordinator: Stitziel, Nathan Oliver
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.